drug · small molecule
mirdametinib
Phase 2updated 6mo agoby SpringWorks Therapeutics Inc🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.
targets
Dual specificity mitogen-activated protein kinase kinase 1Dual specificity mitogen-activated protein kinase kinase 2
all catalysts(0)
nothing on the calendar yet
Trials studying mirdametinib
- phase1Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
- phase2A Study of Mirdametinib in People With Central Nervous System Tumors
- phase1A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
- —Individual Patient Compassionate Use of Mirdametinib
- phase2MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
- phase2Mirdametinib + BGB-3245 in Advanced Solid Tumors
- phase2Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
- phase1To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that